IP Library Granted Patent US 9,365,838
Granted Patent B2
US 9,365,838 · App. 14/087,307 · Granted Jun 14, 2016

Conjugates of biomolecules to nanoparticles

Inventors: Theo Nikiforov (Carlsbad, CA); Daniel Mazur (San Diego, CA); Xinzhan Peng (Carlsbad, CA); Tommie Lloyd Lincecum (Houston, TX); Yuri Belosludtsev (The Woodlands, TX); Howard Reese (Poway, CA); Dmitriy Gremyachinskiy (San Francisco, CA); Roman Rozhkov (Redwood City, CA); John Mauro (Burlingame, CA); Joseph Beechem (Eugene, OR); Eric Tulsky (Berkeley, CA); Imad Naasani (Manchester, GB); Kari Haley (Eugene, OR); Joseph Treadway (Eugene, OR)
Assignee: Life Technologies Corporation
C12N9/1241C07H19/20C12N9/1252C12Q1/6869
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,365,838
App. No.
14/087,307
Granted
Jun 14, 2016
Kind
B2
Abstract

Disclosed herein are conjugates comprising a biomolecule linked to a label that have biological activity and are useful in a wide variety of biological applications. For example, provided herein are polymerase-nanoparticle conjugates including a polymerase linked to a nanoparticle, wherein the conjugate has polymerase activity. Such conjugates can exhibit reduced aggregation and improved stochiometries wherein the average biomolecule:nanoparticle ratio approaches or equals 1:1. Also disclosed herein are improved methods for preparing such conjugates, and methods and systems for using such conjugates in biological applications such as nucleotide incorporation, primer extension and single molecule sequencing.

Claims (20)

1. A composition, comprising a polymerase-nanoparticle conjugate including a polymerase linked to a nanoparticle, wherein the conjugate has polymerase activity, and wherein the polymerase-nanoparticle conjugate includes a template nucleic acid molecule, a polymerization initiation site, and lacks a helicase.

2. The composition of claim 1 , wherein the polymerase activity of the conjugate is at least 1% relative to the polymerase activity of the unconjugated polymerase.

3. The composition of claim 2 , wherein the polymerase activity is at least 70% relative to the polymerase activity of the unconjugated polymerase.

4. The composition of claim 1 , wherein the polymerase comprises a His tag.

5. The composition of claim 1 , wherein the polymerase comprises one member of a binding pair and the nanoparticle comprises a complementary member of the binding pair.

6. The composition of claim 1 , wherein the polymerase is a DNA polymerase.

7. The composition of claim 6 , wherein the DNA polymerase is at least 95% identical to a DNA polymerase selected from the group consisting of: Phi-29 DNA polymerase, B103 DNA polymerase, the Klenow fragment of E. coli DNA polymerase and HIV reverse transcriptase.

8. The composition of claim 1 , wherein the polymerase link is selected from one of a group consisting of: covalent bonding, affinity bonding and electrostatic bonding.

9. The composition of claim 1 , wherein the nanoparticle has a surface coating including a ligand selected from the group consisting of: a DHLA-based ligand, a polycyclic acid-based ligand, a bipeptide ligand and a tridentate thiol-based ligand.

10. The composition of claim 1 , wherein the nanoparticle includes a DHLA-based ligand coating.

11. The composition of claim 1 , wherein the nanoparticle includes a polycyclic acid-based ligand coating.

12. The composition of claim 1 , wherein the nanoparticle includes a tripodal thiol-based ligand coating.

13. The composition of claim 1 , wherein the nanoparticle includes a dipeptide-based coating.

14. The composition of claim 1 , wherein the nanoparticle is positioned relative to the polymerase to perform an energy transfer reaction.

15. The composition of claim 1 , wherein the nanoparticle is positioned to undergo FRET with a labeled nucleotide bound to the nucleotide binding site of the polymerase.

16. The composition of claim 15 , wherein labeled nucleotide further comprises an Alexa Fluor dye linked to the terminal phosphate of the nucleotide, and the nanoparticle undergoes FRET with the Alexa Fluor dye with a FRET efficiency of at least 20%.

17. The composition of claim 1 , where the polymerase includes an N-terminal cysteine, and where N-terminal cysteine is linked to the nanoparticle through a covalent bond.

18. The composition of claim 17 , wherein the covalent bond is formed between a thioester surface ligand of the nanoparticle and a thiol group of the N-terminal cysteine.

19. The composition of claim 17 , wherein the covalent bond is formed between an aldehyde surface ligand of the nanoparticle and a thiol group of the N-terminal cysteine.

20. The composition of claim 1 , further comprising a template nucleic acid molecule and a nucleotide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2016
From: NIKIFOROV, THEO; MAZUR, DANIEL; PENG, XINZHAN; LINCECUM, TOMMIE LLOYD, JR.; BELOSLUDTSEV, YURI; REESE, HOWARD; GREMYACHINSKIY, DMITRIY; ROZHKOV, ROMAN; MAURO, JOHN M.; BEECHEM, JOSEPH; TULSKY, ERIC; NAASANI, IMAD; HALEY, KARI; TREADWAY, JOSEPH A.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 038336/0702 →
Continuity (13)
Division 12748355 · Mar 26, 2010
Provisional Application 61164324 · Mar 27, 2009
Provisional Application 61184770 · Jun 5, 2009
Provisional Application 61242771 · Sep 15, 2009
Provisional Application 61245457 · Sep 24, 2009
Provisional Application 61263974 · Nov 24, 2009
Provisional Application 61289388 · Dec 22, 2009
Provisional Application 61293618 · Jan 8, 2010
Provisional Application 61293616 · Jan 8, 2010
Provisional Application 61299919 · Jan 29, 2010
Provisional Application 61299917 · Jan 29, 2010
Provisional Application 61307356 · Feb 23, 2010
Related Publication 20140308730A1 · Oct 16, 2014